Tariff Tensions: How Pharma Can Prepare for Supply Chain & Cost Disruption
U.S. tariff policies are shifting fast and pharma companies dependent on global supply chains are feeling the strain. With new tariffs on APIs, excipients, and finished drug products climbing as high as 250%, the cost of inaction can be steep: disrupted supply, stalled launches, and reduced patient access.
Contingency planning can’t wait until the tariffs hit. Companies must assess risks, diversify manufacturing, and model financial impact now. Our experts can help you build data-driven strategies, evaluate sourcing options, and fast-track implementation timelines through programs like CMO Compass.
From inventory optimization to supplier audits, we partner with you to safeguard supply continuity, maintain compliance, and protect business resilience — so your organization can navigate tariff uncertainty with confidence and speed.
Related Resources
The Cost of Poor Project Management
Project Management isn’t for the faint of heart. There is a shockingly high rate of project failure… but on the other hand, great project management can be a key differentiator that leads a company...
Successfully Passing MHRA Inspections for Overseas Manufacturing Sites
ProPharma offers GMP and GDP compliance services from clinical development to commercial distribution of the products' lifecycle. ProPharma’s Compliance and Quality team completed the first on-site...
Navigating the Generic Drug Application and Approval Process
Navigating the generic drug application and approval process can be challenging. From pre-filing through post-approval, find out exactly what needs to be done for your Abbreviated New Drug...